E3 Breast Cancer Taxotere Combination

• Status: Completed
• Trial end date: 2009-01-01
• Target enrollment: 0
• Participant gender: Female

Summary

To assess the efficacy of ZD6474 in combination with docetaxel in the treatment of ABC using the progression event count methodology

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Genzyme, a Sanofi Company
• Treatments: Docetaxel

Criteria

Inclusion Criteria:

• Females with histological/cytological confirmation of breast cancer.

• Subjects with a measurable lesion or bone lesions

Exclusion Criteria:

• Previous radiotherapy within 6 weeks

• Significant cardiac events, arrhythmias or other cardiac conditions